Skip to main content

Advertisement

Table 4 Costs incremental health outcomes and cost-utility of pre-referral antimalarial treatments by healthcare provider

From: Cost effectiveness of pre-referral antimalarial treatment in severe malaria among children in sub-Saharan Africa

Scenario Intervention Costs for a cohort of 1000 children ($) DALYs DALYs averted Incremental cost ($) ICER ($ per DALY averted)
Base model No treatment 0.89 20,122
CHW 85,491 4587 15,535 85,490 5.50
PHF 88,961 7512 12,610 88,960 7.05
THF 123,711 2186 17,936 123,710 6.90
Probabilistic sensitivity analysis No treatment 0.88 [0.88–0.88] 19,529 [15,315, 24,737]
CHW 68,428 [43,362, 100,703] 5413 [3091, 8430] 13,276 [9534, 17,684] 68,427 [43,361, 100,702] 5.11 [3.01, 8.21]
PHF 73,825 [47,531, 103,875] 8328 [5030, 12,531] 9993 [6180, 14,429] 73,825 [47,530, 103,874] 7.30 [5.30, 11.20]
THF 114,903 [91,842, 145,168] 3111 [1801, 5005] 15,801 [11,990, 20,375] 114,902 [91,841, 145,167] 7.14 [5.10, 10.92]
  1. CHW community healthworker, PHF primary health facility, THF tertiary health facility, ICER incremental cost-utility ratio, cost cost for treating one child